38 results about "Infertility treatments" patented technology

The present invention concerns the use of an agonist of an hypothalamic hormone for the preparation of a pharmaceutical agent to support the luteal phase during infertility treatment of female mammals and more specifically of woman. According to this invention, the pharmaceutical agent is suitable to be used for supporting the luteal phase after a spontaneous ovulation or after stimulation of follicular growth, trigger of final follicular maturation and ovulation with one or several additional agents.

Provided is a multiple birth prognostic tool that is used to analyze data in order to predict a multiple birth event in a female human patient undergoing an infertility treatment. The MBP prognostic tool may also be used to enhance the accuracy of diagnostic or prognostic tests that predict embryo viability. The MBP prognostic tool of the present invention may be clinic specific or it may be modified to be used in a multi-clinic approach.

Novel sequence tagged sites (STSs), probes and primers useful, e.g., for detecting the presence or absence of an STS in a sample, and methods of using these STSs, probes and primers, e.g., in methods of detecting alterations in the Y chromosome are disclosed. These compositions are also useful in methods of diagnosing or aiding in the diagnosis and / or cause of reduced sperm count and in methods of predicting or aiding in the prediction of the likelihood of success of infertility treatments.

Provided is a multiple birth prognostic tool that is used to analyze data in order to predict a multiple birth event in a female human patient undergoing an infertility treatment. The MBP prognostic tool may also be used to enhance the accuracy of diagnostic or prognostic tests that predict embryo viability. The MBP prognostic tool of the present invention may be clinic specific or it may be modified to be used in a multi-clinic approach.

The present invention provides a composition including a polar organic extract of Eurycoma longifolia and a fraction derived from the polar organic extract, said composition comprising of quassinoids, coumarins, their glycosides, analogues and derivatives, which exhibits bioactivity of increasing spermatozoa production and spermatozoa quality in terms of morphology and motility, as well as increasing testosterone synthesis and release from cells of males. The extraction method of E. longifolia plant to produce the polar organic extract, and the subsequent purification to produce the fraction of polar organic extract containing the quassinoids, coumarins, their glycosides, analogues and derivatives, and uses for manufacturing a preparation for infertility treatment are also provided. The fraction of polar organic extract containing the quassinoids, coumarins, their glycosides, analogues and derivatives is formulated for medical applications via several routes of administration.

The invention provides an animal model with male reproductive disorders of a non-human mammalian animal, as well as a preparation method and application of the animal model, and further identifies the functions of a Prss37 gene and a protein. The Prss37 gene of the animal model is inactivated, thereby affecting the appearance of ADAM3 in mature sperms produced by the animal model, indirectly affecting the combination of the sperms-zona pellucida and the migration of the sperms from the uterus to the oviduct and resulting in the serious male reproductive disorders. The model, the Prss37 gene and the protein thereof can be used for screening ADAM3 ripening accelerators, as well as sterility infertility treatment agents or contraceptive medicaments.

The invention provides application of decidua NK cells and decidua NK cell exosomes from cell subsets in preparing drugs and auxiliary therapeutic agents for treating diseases related to infertility.Experiments prove that the exosomes treat endometrium growth disorders by promoting endometrial thickness increasing, improving endometrial cell activity, reducing endometrial cell damage, promoting VEGF expression, maintaining stem features of endometrium matrix cells and stimulating proliferation, so that the pregnancy success rate of endometrium damage model mice is increased to 50-70% from 20%; and the exosomes treat diseases related to maternal-fetal immunologic tolerance disorders by playing a role of immunologic tolerance, reducing a spontaneous abortion rate and improving a help T lymphocyte level. Besides, the exosomes can effectively increase the developmental rate of zygotes fertilized no matter in vitro or in vivo in a multiple mode, meanwhile, an in-vitro fertilization rate, an implantation rate of implantation and a birth rate are also increased, and positive assisting effects on infertility treatment are achieved.

The present invention relates to pharmaceutical compositions comprising a peptide that stimulates the release of gonadotropins and sexual steroids. More specifically, the present invention provides pharmaceutical compositions comprising kisspeptin, preferably in the kp-10 form, or derivatives thereof, for use in ovulation cycle inducing and / or infertility treatment programs. The formulations according to the present invention belong to two main groups: injectable solutions and implantable formulations. The injectable solutions according to the present invention can be divided into immediate release solutions and prolonged action solutions. The implantable formulations according to the present invention can be prepared using an RTV silicone elastomer, a rapid vulcanization silicone elastomer or a rapid vulcanization silicone elastomer with a release modulator.

The invention discloses a traditional Chinese medicine composition used for nursing and treating infertility of women and belongs to the technical field of traditional Chinese medicines. Aiming at overcoming the defect that in the prior art, the existing infertility treatment effect is poor. The traditional Chinese medicine composition used for treating infertility of women provided by the invention is prepared from the following raw materials in parts by weight: 8-20 parts of Chinese angelica, 5-15 parts of Szechwan lovage rhizome, 5-15 parts of white paeony root, 3-10 parts of gentiana macrophylla, 10-25 parts of cowherb seed, 5-15 parts of rhizoma alismatis, 10-20 parts of raspberry, 3-10 parts of rhizoma cyperi, 10-20 parts of dried tangerine or orange peel, 5-15 parts of salviae miltiorrhizae, 8-20 parts of myrrh, 5-12 parts of cassia twig, 10-20 parts of moutan bark, 5-15 parts of donkey-hide gelatin, 3-10 parts of semen cuscutae, 5-15 parts of combined spicebush root, 10-25 parts of fructus alpiniae oxyphyllae, 5-20 parts of the bark of eucommia, 10-25 parts of motherwort herb, 10-20 parts of rhizoma corydalis, 3-10 parts of rhizoma acori graminei, 5-15 parts of fingered citron, 3-10 parts of curcuma aromatica, 5-12 parts of asarum, 10-15 parts of medlar, 10-20 parts of platycodon grandiflorum, 3-10 parts of divaricate saposhnikovia root and 5-15 parts of dried ginger. The traditional Chinese medicine composition has good treatment effect in the aspect of treating infertility of women, and has a low side effect and an obvious clinical popularization value.

The invention relates to the technical field of medicines, and provides applications of uterine cavity fluid-derived exosome in preparation of drugs and adjuvant therapeutic agents for treating infertility related diseases. Through the verification of experiments, exosome realizes the treatment or relieving of endometrial growth disorders by promoting the increasing of the thickness of endometrium, enhancing the activity of endometrial cells, reducing the damages to intimal cells, promoting VEGF expression, maintaining the dryness of endometrial stromal cells and stimulating proliferation; andthrough the realizing of the treating or relieving of maternal-fetal immune tolerance disorder-related diseases by achieving immune tolerance effects, treating spontaneous abortion and enhancing T helper lymphocyte levels, a novel theoretical basis can be provided for infertility treatment. In addition, for both fertilized eggs being fertilized in vivo or fertilized in vitro, the exosome can effectively enhance developmental rates in multiples; and implantation rates and farrowing rates of in vitro fertilization transplantation can be increased as well, so that positive auxiliary effects on infertility treatment can be achieved.

Beneficiaries are registered by an insurance provider for an insurance coverage policy for fertility diagnosis and treatable infertility conditions using either manual or online registration applications over a communications network. Using, knowledge base systems, prospective beneficiary personal descriptor information is matched with terms and conditions information preloaded into the insurance company computer system to generate a customized contract for delivery of infertility treatment services to different categories of beneficiaries. Beneficiaries may range in age from newborn infants up to adults. However, infertility treatment services are not provided either until the beneficiaries reach childbearing age or until the policies of adult beneficiaries vest over a designated time period. Adults can purchase infertility insurance naming their infant child as beneficiary and pay premiums over time until the child reaches childbearing age. Once the child reaches childbearing age, the insurance policy can be utilized by the beneficiary or can be transferred.

The invention discloses a traditional Chinese medicine composition used for treating immune infertility, and a preparation method and application thereof. According to the composition, with Mongolian milkvetch root, largehead atractylodes rhizome, Asiatic cornelian cherry fruit, and medlar, spleen invigorating, kidney nourishing, immunity enhancing, and abnormal immune suppression effects are provided; with salvia miltiorrhiza, blue turmeric rhizome, red peony root, peony tree root bark, pangolin, cowherb seed, and white peony root, blood circulation is activated, stasis is removed, excessive antigens can be removed, immune complex generation can be prevented, and blood circulation is improved; with paniculate swallowwort, ramie root, divaricate saposhnikovia, Mongolian milkvetch root, and black cicada slough, antibody generation is inhibited, and good desensitization effect is provided; and with glabrous greenbrier rhizome, coix seed, licorice root, and giant knotweed rhizome, heat clearing, detoxifying, dampness removing, and humoral immune inhibition effects are provided. As results of clinical experiments, the traditional Chinese medicine composition provided by the invention has good immune infertility treatment effect, and is safe and reliable. The composition can be widely applied in treatments of immune infertility.

Beneficiaries are registered by an insurance provider for an insurance coverage policy for fertility diagnosis and treatable infertility conditions using either manual or online registration applications over a communications network. Using, knowledge base systems, prospective beneficiary personal descriptor information is matched with terms and conditions information preloaded into the insurance company computer system to generate a customized contract for delivery of infertility treatment services to different categories of beneficiaries. Beneficiaries may range in age from newborn infants up to adults. However, infertility treatment services are not provided either until the beneficiaries reach childbearing age or until the policies of adult beneficiaries vest over a designated time period. Adults can purchase infertility insurance naming their infant child as beneficiary and pay premiums over time until the child reaches childbearing age. Once the child reaches childbearing age, the insurance policy can be utilized by the beneficiary or can be transferred.

The invention relates to traditional Chinese medicine red sage root-motherwort powder for treating infertility. The traditional Chinese medicine red sage root-motherwort powder is mainly used for solving the problem that the current drugs for treating infertility are poor in treatment effect and have side effects. The traditional Chinese medicine red sage root-motherwort powder is prepared through the steps of weighing 9g of prepared monkshood, 9g of prepared kusnezoff monkshood, 15g of red sage root and 15g of motherwort, baking all the traditional Chinese medicines except for asarum, and then, co-grinding into fine powder together with asarum. The usage and dosage are as follows: the powder is orally taken once in the morning, noon and evening of a day by 17g every time, and liquor is taken as a guide; the powder is orally taken about one week after menstruation; a treatment course comprises the continuous taking of two prescriptions; in case of not work, the powder can be orally taken in such a way at next menstrual onset. The traditional Chinese medicine red sage root-motherwort powder has the aims and advantages that the total effective rate for infertility treatment is over 95%, and the cure rate is over 80%. The traditional Chinese medicine red sage root-motherwort powder is free from toxic and side effects.

The invention relates to a traditional Chinese medicine coptis-angelica pill for treating infertility. The traditional Chinese medicine coptis-angelica pill is mainly used for solving the problem that the current drugs for treating infertility are poor in treatment effect and have side effects. The traditional Chinese medicine coptis-angelica pill is prepared through the steps of weighing 10g of coptis root, 50g of prepared rehmannia root, 10g of angelica and 5g of licorice root, dipping for one night with medicated wine, baking, co-grinding into powder, and forming pills with honey. The usage and dosage are as follows: the powder is orally taken once in the morning and evening of a day by 9g every time. The traditional Chinese medicine coptis-angelica pill has the aims and advantages that the total effective rate for infertility treatment is over 95%, and the cure rate is over 80%. The traditional Chinese medicine coptis-angelica pill is free from toxic and side effects.

A method of inducing ovulation in a female suffering from anovulatory infertility which comprises administering to said female two or more daily doses of at least one aromatase inhibitor. A method for augmenting ovulation in an ovulating female suffering from unexplained infertility or another type of ovulatory infertility which comprises administering to said female two or more daily doses of at least one aromatase inhibitor early in one or more menstrual cycles. A method of substantially reducing dosage levels of follicle stimulating hormone (FSH) for administration to a female undergoing infertility treatment which comprises administering a combination of two or more daily doses of at least one aromatase inhibitor (AI) with a plurality of daily doses of follicle stimulating hormone (FSH). A method of increasing response to a follicle stimulating hormone from a female who is a poor responder to follicle stimulation, which comprises administering a combination of two or more daily doses or at least one aromatase inhibitor (AI) with a plurality of daily doses of follicle stimulating hormone (FSH). Also disclosed are related pharmaceutical preparations and uses.

The present invention pertains to improved FSH preparations which are capable of stimulating sex steroid release at much lower concentration than the commonly used urinary FSH or recombinant FSH obtained from CHO cells and which act independent of cAMP signaling These improved FSH preparations can be used in infertility treatment.

The invention relates to a traditional Chinese medicine golden cypress and rhizoma anemarrhenae pill for treating infertility and mainly solves the problems that the conventional medicine for treating infertility is poor in curative effect and has side effects. The traditional Chinese medicine golden cypress and rhizoma anemarrhenae pill is prepared from 110g of golden cypress (peeling, uniformly frying with salt and wine to brown, and taking clean powder), 100g of rhizoma anemarrhenae (unhairing, cleaning, steeping in wine for one night, finely frying, and taking clean powder), 140g of semen euryales, 84g of fructus psoraleae (stir-frying with new tiles, and taking clean powder ), 96g of walnut kernel (shelling and grinding) and 30g of fructus amomi (frying half of fructus amomi with 15g of pepper, removing the pepper, and using half of raw fructus amomi). The usage and dosage are as follows: the Chinese medicinal herbs are ground into fine powder, and the fine powder is refined with honey into pills; taking twice every day and 1.5-3g each time, and taking with dilute salt soup. The traditional Chinese medicine golden cypress and rhizoma anemarrhenae pill has the advantages that the total effective rate of infertility treatment is 95 percent above, and the cure rate is 80 percent above; the traditional Chinese medicine golden cypress and rhizoma anemarrhenae pill has no toxic or side effects.

The invention relates to a traditional Chinese medicine saltpeter-rhubarb pill for treating infertility. The traditional Chinese medicine saltpeter-rhubarb pill is mainly used for solving the problem that the current drugs for treating infertility are poor in treatment effect and have side effects. The traditional Chinese medicine saltpeter-rhubarb pill is prepared through the steps of weighing 240g of rhubarb root, 180g of saltpeter, 60g of ginseng and 60g of licorice root, firstly cooking the rhubarb root with 1,500ml of bitter wine, stirring, adding the rest medicines until the liquid is 1,000ml, and decocting with low fire until pilling can be carried out when the liquid is 500ml. The usage and dosage are as follows: the pill is orally taken once in the morning and evening of a day by 20g every time. The traditional Chinese medicine saltpeter-rhubarb pill has the aims and advantages that the total effective rate for infertility treatment is over 95%, and the cure rate is over 80%. The traditional Chinese medicine saltpeter-rhubarb pill is free from toxic and side effects.

The present invention pertains to improved FSH preparations which are capable of stimulating sex steroid release at much lower concentration than the commonly used urinary FSH or recombinant FSH obtained from CHO cells and which act independent of cAMP signaling These improved FSH preparations can be used in infertility treatment.

The present invention relates to a new application of phosphodiesterase inhibitors for couple infertility treatment which forms an effective alternative to the invasive assisted reproductive techniques such as conjugal artificial insemination and which consists of the transvaginal administration of a phosphodiesterase inhibitor immediately before and / or after coitus. It also relates to dosage forms suitable for the intravaginal administration of phosphodiesterase inhibitors.

The invention relates to a traditional Chinese medicine five-seed pill for treating infertility and mainly solves the problems that the conventional medicine for treating infertility is poor in curative effect and has side effects. The traditional Chinese medicine five-seed pill is prepared from 240g of the fruit of Chinese wolfberry, 60g of the fruit of Chinese magnoliavine, 250g of semen cuscutae (steaming with wine and mashing), 120g of raspberry and 60g of semen plantaginis. The usage and dosage are as follows: the Chinese medicinal herbs are ground into fine powder, and the fine powder is refined with honey into pills; taking twice every day and 6g each time, and taking with rice water or warm wine under the condition of an empty stomach or before eating. The traditional Chinese medicine five-seed pill has the advantages that the total effective rate of infertility treatment is 95 percent above, and the cure rate is 80 percent above; the traditional Chinese medicine five-seed pill has no toxic or side effects.

The invention relates to a traditional Chinese medicine angelica sinensis and musk pill for treating infertility and mainly solves the problems that the conventional medicine for treating infertility is poor in curative effect and has side effects. The traditional Chinese medicine angelica sinensis and musk pill is prepared from 500g of cornel (steeping in wine and extracting cornus), 250g of fructus psoraleae (steeping in wine and drying), 125g of angelica sinensis and 3g of musk. The usage and dosage are as follows: the Chinese medicinal herbs are ground into fine powder, and the fine powder is refined with honey into pills; taking one time every day and 8g each time, and taking with rice water or warm wine before sleep. The traditional Chinese medicine angelica sinensis and musk pill has the advantages that the total effective rate of infertility treatment is 95 percent above, and the cure rate is 80 percent above; the traditional Chinese medicine angelica sinensis and musk pill has no toxic or side effects.

The invention discloses application of a PTP1B (protein tyrosine phosphates 1b) inhibitor and a PTP1B gene, and in particular relates to the PTP1B inhibitor in preparation of a medicine for treating infertility (a), and a medicine for improving acrosome reaction (b) and or improving fertility rate (c). Experiments indicate that: the PTP1B inhibitor can be used for effectively improving the acrosome reaction and fertility rate. According to the application, infertility patients with obesity or normal body weight can be screened by detecting whether a PTP1B is highly expressed in a body or not, so that a treatment scheme for the infertility patients can be determined, and is more flexible, easier and more economical that that of common diagnostic treatment in a traditional infertility treatment process.

The invention discloses the application of the protein Secp43 or its coding gene in regulating the male fertility of Drosophila melanogaster. The amino acid sequence of the protein Secp43 is shown in SEQ ID NO.2. The present invention finds that knocking out the coding gene Secp43 can make the Drosophila melanogaster male sterile, the bundled sperm cannot be separated, and the immature sperm cannot enter the seminal vesicle, which may be the main reason for the male infertility. Therefore, the present invention screens out a new protein related to male sterility of Drosophila melanogaster, and in view of the homology of some proteins between Drosophila and humans, it will help us to find a new therapeutic target for infertility. And in-depth research on the regulatory mechanism of Secp43 causing male sterility in Drosophila melanogaster from the perspective of RNA binding proteins will help us find new therapeutic targets for infertility.